ZoomInfo, a source for business information for people and companies around the world, and Main Sequence Technologies, the vendor of applicant tracking system PCRecruiter, have announced a partnership that will give recruiters utilizing the ATS access to ZoomInfo’s capabilities.
In the past, ZoomInfo has also partnered with SalesForce.com, AIRS, and other programs “to accelerate and simplify business processes, leverage specialized search capabilities and access the most current, relevant information on professionals and their companies,” a company spokesperson said.
Jonathan Stern, Founder, CEO and Chief Scientist, said “Humans just can’t compete with the scope, depth and speed of technology. Our goal is to continue delivering high value in our key markets and make business information freely available to business professionals.”
Both companies report that the partnership will bring ZoomInfo capabilities to one of PCRecruiter’s largest clients, the MRINetwork, a global recruitment organization with over 1000 franchisees and affiliates.
Popularity: 8% [?]










October 24th, 2008 at 7:17 am
You should be aware that MRINetwork have a history of not representing the truth about its franchisees. They represented someone as a regular franchised office for year after his franchise agreement had expired. This continued whilst his debts grew to massive levels. They fooled all the other MRINetwork franchisees as well as clients with this deception. Take a look at the facts on http://www.cdicorp.info and form your own opinion on the ethics and business practices of this franchised recruitment company.
October 30th, 2008 at 4:42 pm
While I can’t speak for the distant past, since becoming involved with MRI in 2003, we have experienced a company that cares a great deal about their owners. I have seen zero evidence of systematic ethical or business practice issues while I have seen a great deal of money being made by numbers of offices.
Disclosure: we make money when new units are sold, but that does not impact my opinion on the subject above.